Mark Lakshmanan (M Lakshmanan)

Publication Activity (10 Years)

Years Active: 2018-2022
Publications (10 Years): 2

Top Topics

Glycemic Control

Mesenchymal Stem Cells

Top Venues

Diabetic medicine : a journal of the British Diabetic Association

European journal of heart failure

This page only lists publications with an associated author ORCID identifier.

Publications

Kelley R H Branch, Gilles R Dagenais, Álvaro Avezum, Jan Basile, Ignacio Conget Donlo, William C Cushman, Petr Jansky, Mark Lakshmanan, Fernando Tomás Lanas Zanetti, Lawrence Alan Leiter, Prem Pais, Nana Pogosova, Peter Johann Raubenheimer, Lars Ryden, Jonathan Edward Shaw, Wayne Huey Herng Sheu, Theodora Temelkova-Kurktschiev, M Angelyn Bethel, Ulagamadesan Venkatesan, Ramasundarahettige Chinthanie, Jeffrey L Probstfield
Dulaglutide and cardiovascular and heart failure outcomes in patients with and without heart failure: a post-hoc analysis from the REWIND randomized trial. European journal of heart failure 24 (10) (2022)
S I Sherman, R T Kloos, R M Tuttle, A Pontecorvi, H Völzke, K Harper, C Vance, J T Alston, A L Usborne, K W Sloop, Mark Lakshmanan
No calcitonin change in a person taking dulaglutide diagnosed with pre-existing medullary thyroid cancer. Diabetic medicine : a journal of the British Diabetic Association 35 (3) (2018)